OTC · EMMA
Emmaus Life Sciences, Inc.
$0.04-$0.00 (-12.0%)
Emmaus Life Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.95% below the high.
Loading market information…
OTC · NTRR · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Neutra Corp.’s quoted price sits in the upper half of its reported 52-week range, 33.33% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Neutra Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Neutra Corp. specializes in the research, development, and provision of hemp-derived nutraceuticals. Its product portfolio features items such as CBD-infused sports creams, in addition to a variety of other health and wellness goods. Established in 2011, the company is headquartered in Sugar Land, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.04-$0.00 (-12.0%)
Emmaus Life Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.95% below the high.
$0.06$0.00 (0.0%)
Unity Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.19% below the high.
$0.00+$0.00 (+12.5%)
Halberd Corporation’s quoted price sits in the upper half of its reported 52-week range, 10.0% below the high.
$3.29$0.00 (0.0%)
Helix BioMedix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.38% below the high.
$0.00$0.00 (0.0%)
Opus Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
$0.05$0.00 (0.0%)
Orgenesis Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.87% below the high.
$0.00$0.00 (0.0%)
Oxford Investments Holdings Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Marizyme, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.3% below the high.
